References
- Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol 2004;6:97–105
- Cogswell JP, Godlevski MM, Wisely GB, et al. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol 1994;153:712–23
- D'Souza MJ, Jin Z, Oettinger CW. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-kappaB. J Interferon Cytokine Res 2005;25:311–20
- Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990;10:2327–34
- Barnes PJ, Adcock IM. NF-kappa B: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci 1997;18:46–50
- Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066–71
- Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 2010;86:211–18
- Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 2009;1:a000141 (1–14)
- Tilstra JS, Clauson CL, Niedernhofer LJ, Robbins PD. NF-kappaB in aging and disease. Aging Dis 2011;2:449–65
- Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 2003;92:522–8
- Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 2011;108:1122–32
- Kawano S, Kubota T, Monden Y, et al. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol 2006;291:H1337–44
- Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161–72
- Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981–8
- D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies. Mol Interv 2002;2:22–35
- Gupta S, Young D, Maitra RK, et al. Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol 2008;375:637–49
- Sostres C, Gargallo CJ, Arroyo MT, Lanas A. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010;24:121–32
- Cooper SR, Taylor JK, Miraglia LJ, Dean NM. Pharmacology of antisense oligonucleotide inhibitors of protein expression. Pharmacol Ther 1999;82:427–35
- Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999;1489:31–44
- Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347–55
- Arnedo A, Espuelas S, Irache JM. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm 2002;244:59–72
- Gayakwad SG, Bejugam NK, Akhavein N, et al. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul 2009;26:692–700
- Lu W, Sun Q, Wan J, et al. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006;66:11878–87
- Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006;14:45–53
- Bejugam NK, Gayakwad SG, Uddin AN, D'Souza MJ. Microencapsulation of protein into biodegradable matrix: a smart solution cross-linking technique. J Microencapsul 2013;30:274–82
- Siwale RC, Oettinger CW, Addo R, et al. The effect of intracellular delivery of catalase and antisense oligonucleotides to NF-kappaB using albumin microcapsules in the endotoxic shock model. J Drug Target 2009;17:701–9
- Akhavein N, Oettinger CW, Gayakwad SG, et al. Treatment of adjuvant arthritis using microencapsulated antisense NF-kappaB oligonucleotides. J Microencapsul 2009;26:223–34
- Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000;102:IV14–23
- Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569–82
- French BA, Kramer CM. Mechanisms of post-infarct left ventricular remodeling. Drug Discov Today Dis Mech 2007;4:185–96
- Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 1998;98:1699–702
- Brower GL, Henegar JR, Janicki JS. Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. Am J Physiol 1996;271:H2071–8
- Huang M, Hester RL, Guyton AC. Hemodynamic changes in rats after opening an arteriovenous fistula. Am J Physiol 1992;262:H846–51
- Brower GL, Janicki JS. Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 2001;280:H674–83
- Hall G, Hasday JD, Rogers TB. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 2006;41:580–91
- Wang X, Ren B, Liu S, et al. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol 2003;94:752–63
- Jobe LJ, Melendez GC, Levick SP, et al. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol 2009;297:H1462–8
- Cosgrove D, Harvey C. Clinical uses of microbubbles in diagnosis and treatment. Med Biol Eng Comput 2009;47:813–26
- Dijkmans PA, Juffermans LJ, Musters RJ, et al. Microbubbles and ultrasound: from diagnosis to therapy. Eur J Echocardiogr 2004;5:245–56
- Shohet RV, Chen S, Zhou YT, et al. Echocardiographic destruction of albumin microbubbles directs gene delivery to the myocardium. Circulation 2000;101:2554–6
- Khan A, Benboubetra M, Sayyed PZ, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004;12:393–404
- Oettinger CW, D'souza M J, Akhavein N, et al. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kappaB. J Microencapsul 2007;24:337–48
- Shastri PN, Ubale RV, D'Souza MJ. Implementation of mixture design for formulation of albumin containing enteric-coated spray-dried microparticles. Drug Dev Ind Pharm 2013;39:164–75
- Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 2010;197:55–86
- Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63:185–98
- Onai Y, Suzuki J, Maejima Y, et al. Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol 2007;292:H530–8
- Trescher K, Bernecker O, Fellner B, et al. Adenovirus-mediated overexpression of inhibitor kappa B-alpha attenuates postinfarct remodeling in the rat heart. Eur J Cardiothorac Surg 2004;26:960–7
- Fraccarollo D, Widder JD, Galuppo P, et al. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 2008;118:818–27
- Zimmer HG, Heckmann M, Lortet S. Cardiovascular response to triiodothyronine in Sprague-Dawley and spontaneously hypertensive rats. Cardioscience 1993;4:157–62
- Frantz S, Ducharme A, Sawyer D, et al. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol 2003;35:685–94
- Chancey AL, Brower GL, Peterson JT, et al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002;105:1983–8